CN1044476C - 螯合物和其制备方法 - Google Patents
螯合物和其制备方法 Download PDFInfo
- Publication number
- CN1044476C CN1044476C CN93102147A CN93102147A CN1044476C CN 1044476 C CN1044476 C CN 1044476C CN 93102147 A CN93102147 A CN 93102147A CN 93102147 A CN93102147 A CN 93102147A CN 1044476 C CN1044476 C CN 1044476C
- Authority
- CN
- China
- Prior art keywords
- group
- oxygen base
- germanium
- carbon atoms
- phthalocyanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000013522 chelant Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title description 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 238000002512 chemotherapy Methods 0.000 claims abstract description 13
- 229910052732 germanium Inorganic materials 0.000 claims abstract description 13
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000001301 oxygen Substances 0.000 claims description 127
- 229910052760 oxygen Inorganic materials 0.000 claims description 127
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 122
- 125000004432 carbon atom Chemical group C* 0.000 claims description 69
- 150000001875 compounds Chemical class 0.000 claims description 62
- -1 4Be hydrogen Chemical class 0.000 claims description 60
- 150000003431 steroids Chemical class 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 42
- 125000003545 alkoxy group Chemical group 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 229910052799 carbon Inorganic materials 0.000 claims description 25
- 125000001931 aliphatic group Chemical group 0.000 claims description 22
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 235000010290 biphenyl Nutrition 0.000 claims description 12
- 238000005424 photoluminescence Methods 0.000 claims description 10
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- YCOZIPAWZNQLMR-UHFFFAOYSA-N pentadecane Chemical compound CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- 239000003925 fat Substances 0.000 claims description 6
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 150000001336 alkenes Chemical class 0.000 claims description 4
- 125000001118 alkylidene group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- XIIAYQZJNBULGD-UHFFFAOYSA-N (5alpha)-cholestane Natural products C1CC2CCCCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XIIAYQZJNBULGD-UHFFFAOYSA-N 0.000 claims 1
- PNNXBWWSFIVKQW-UHFFFAOYSA-N [O].CCCCCCCCCCCCCCCC Chemical compound [O].CCCCCCCCCCCCCCCC PNNXBWWSFIVKQW-UHFFFAOYSA-N 0.000 claims 1
- XIIAYQZJNBULGD-LDHZKLTISA-N cholestane Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 XIIAYQZJNBULGD-LDHZKLTISA-N 0.000 claims 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 abstract description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052782 aluminium Inorganic materials 0.000 abstract description 2
- 239000004411 aluminium Substances 0.000 abstract description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052733 gallium Inorganic materials 0.000 abstract description 2
- 229910052738 indium Inorganic materials 0.000 abstract description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052707 ruthenium Inorganic materials 0.000 abstract description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 abstract 1
- LKKPNUDVOYAOBB-UHFFFAOYSA-N naphthalocyanine Chemical compound N1C(N=C2C3=CC4=CC=CC=C4C=C3C(N=C3C4=CC5=CC=CC=C5C=C4C(=N4)N3)=N2)=C(C=C2C(C=CC=C2)=C2)C2=C1N=C1C2=CC3=CC=CC=C3C=C2C4=N1 LKKPNUDVOYAOBB-UHFFFAOYSA-N 0.000 abstract 1
- 229910052718 tin Inorganic materials 0.000 abstract 1
- 239000002585 base Substances 0.000 description 100
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 52
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 238000001816 cooling Methods 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000035772 mutation Effects 0.000 description 13
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 238000000967 suction filtration Methods 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000002502 liposome Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 150000003222 pyridines Chemical class 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical class C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- OUKLXTIDZQJLOR-UHFFFAOYSA-N benzhydryl(dihydroxy)silane Chemical compound O[SiH](O)C(c1ccccc1)c1ccccc1 OUKLXTIDZQJLOR-UHFFFAOYSA-N 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical class N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 150000004819 silanols Chemical class 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000009834 vaporization Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 4
- BGHCVCJVXZWKCC-UHFFFAOYSA-N tetradecane Chemical compound CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 3
- 235000017491 Bambusa tulda Nutrition 0.000 description 3
- 241001330002 Bambuseae Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000011425 bamboo Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000003098 cholesteric effect Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical group [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 238000010025 steaming Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008016 vaporization Effects 0.000 description 3
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- NDJKXXJCMXVBJW-UHFFFAOYSA-N heptadecane Chemical compound CCCCCCCCCCCCCCCCC NDJKXXJCMXVBJW-UHFFFAOYSA-N 0.000 description 2
- 235000011167 hydrochloric acid Nutrition 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 208000017983 photosensitivity disease Diseases 0.000 description 2
- 231100000434 photosensitization Toxicity 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- IEXRMSFAVATTJX-UHFFFAOYSA-N tetrachlorogermane Chemical class Cl[Ge](Cl)(Cl)Cl IEXRMSFAVATTJX-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000002769 thiazolinyl group Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- IIYFAKIEWZDVMP-UHFFFAOYSA-N tridecane Chemical compound CCCCCCCCCCCCC IIYFAKIEWZDVMP-UHFFFAOYSA-N 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- ZGDVRBVTNMQMEX-LDHZKLTISA-N (8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylhept-6-en-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)=C)C)[C@@]1(C)CC2 ZGDVRBVTNMQMEX-LDHZKLTISA-N 0.000 description 1
- BIQKRILZMDQPHI-BMRADRMJSA-N (e)-heptadec-8-ene Chemical compound CCCCCCCC\C=C\CCCCCCC BIQKRILZMDQPHI-BMRADRMJSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical class COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N Arbutin Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-IGMARMGPSA-N Carbon-12 Chemical compound [12C] OKTJSMMVPCPJKN-IGMARMGPSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- MWYULRCIDCNTKC-UHFFFAOYSA-N Cl[SiH2]Cl.c1ccc(cc1)-c1ccccc1 Chemical compound Cl[SiH2]Cl.c1ccc(cc1)-c1ccccc1 MWYULRCIDCNTKC-UHFFFAOYSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 101100001678 Emericella variicolor andM gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 241000353097 Molva molva Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- SVEIAXQRDFEZHA-UHFFFAOYSA-N [O].C(CCCCC)[SiH](C)C Chemical compound [O].C(CCCCC)[SiH](C)C SVEIAXQRDFEZHA-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000003811 acetone extraction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- SPXCIWDWQZPYAF-UHFFFAOYSA-N benzhydryl(hydroxy)silane Chemical class C=1C=CC=CC=1C([SiH2]O)C1=CC=CC=C1 SPXCIWDWQZPYAF-UHFFFAOYSA-N 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 150000002291 germanium compounds Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002398 hexadecan-1-ols Chemical class 0.000 description 1
- CUUJVBDPSUOTIQ-UHFFFAOYSA-N hydroxy-dimethyl-octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[Si](C)(C)O CUUJVBDPSUOTIQ-UHFFFAOYSA-N 0.000 description 1
- MLPRTGXXQKWLDM-UHFFFAOYSA-N hydroxy-methyl-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](O)(C)C1=CC=CC=C1 MLPRTGXXQKWLDM-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- QXHRJCQMYAREHW-UHFFFAOYSA-N n,n-dimethylformamide;tetrachlorogermane Chemical compound CN(C)C=O.Cl[Ge](Cl)(Cl)Cl QXHRJCQMYAREHW-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920006391 phthalonitrile polymer Polymers 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- JLGLQAWTXXGVEM-UHFFFAOYSA-N triethylene glycol monomethyl ether Chemical class COCCOCCOCCO JLGLQAWTXXGVEM-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NLSXASIDNWDYMI-UHFFFAOYSA-N triphenylsilanol Chemical class C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(O)C1=CC=CC=C1 NLSXASIDNWDYMI-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/06—Aluminium compounds
- C07F5/069—Aluminium compounds without C-aluminium linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/003—Compounds containing elements of Groups 4 or 14 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
- C07F7/0836—Compounds with one or more Si-OH or Si-O-metal linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Polyethers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH600/92-1 | 1992-02-27 | ||
| CH60092 | 1992-02-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1075966A CN1075966A (zh) | 1993-09-08 |
| CN1044476C true CN1044476C (zh) | 1999-08-04 |
Family
ID=4190744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93102147A Expired - Fee Related CN1044476C (zh) | 1992-02-27 | 1993-02-26 | 螯合物和其制备方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US5358940A (enExample) |
| EP (1) | EP0558449B1 (enExample) |
| JP (1) | JPH0656839A (enExample) |
| KR (1) | KR100270284B1 (enExample) |
| CN (1) | CN1044476C (enExample) |
| AT (1) | ATE196143T1 (enExample) |
| AU (1) | AU662800B2 (enExample) |
| CA (1) | CA2090772A1 (enExample) |
| DE (1) | DE59310096D1 (enExample) |
| DK (1) | DK0558449T3 (enExample) |
| ES (1) | ES2151502T3 (enExample) |
| FI (1) | FI930831A7 (enExample) |
| GR (1) | GR3034887T3 (enExample) |
| HU (1) | HUT64075A (enExample) |
| IL (1) | IL104874A (enExample) |
| MX (1) | MX9301083A (enExample) |
| NO (1) | NO930719L (enExample) |
| NZ (1) | NZ247000A (enExample) |
| PT (1) | PT558449E (enExample) |
| SG (1) | SG49615A1 (enExample) |
| TW (1) | TW235298B (enExample) |
| ZA (1) | ZA931382B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5484778C1 (en) * | 1990-07-17 | 2001-05-08 | Univ Cleveland Hospitals | Phthalocynine photosensitizers for photodynamic therapy and methods for their use |
| US5179120A (en) * | 1991-06-28 | 1993-01-12 | Cytopharm, Inc. | Porphycene compounds for photodynamic therapy |
| GB9123814D0 (en) * | 1991-11-08 | 1992-01-02 | Johnson Matthey Plc | Photosensitizers |
| TW235298B (enExample) * | 1992-02-27 | 1994-12-01 | Ciba Geigy | |
| GB9405970D0 (en) * | 1994-03-25 | 1994-05-11 | Secr Defence | Substituted phthalocyanines |
| RU2106146C1 (ru) * | 1995-07-17 | 1998-03-10 | Институт элементоорганических соединений РАН | Средство для подавления опухолевого роста |
| US5763602A (en) * | 1996-10-01 | 1998-06-09 | Li; Ying-Syi | Methods of syntheses of phthalocyanine compounds |
| US5872248A (en) * | 1997-03-28 | 1999-02-16 | Case Western Reserve University | Methods for inserting silicon into phthalocyanines and naphthalocyanines |
| IL121440A0 (en) | 1997-07-31 | 1998-01-04 | Yeda Res & Dev | The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives |
| US6645928B1 (en) * | 1999-03-05 | 2003-11-11 | Case Western Reserve University | Hydrophobic liquid photobleaches |
| US8211883B2 (en) * | 2004-04-01 | 2012-07-03 | Case Western Reserve University | Topical delivery of phthalocyanines |
| US7153956B2 (en) * | 2004-08-09 | 2006-12-26 | Silverbrook Research Pty Ltd | Cyanine dye having multifunctional peripheral groups |
| JP2010163473A (ja) * | 2009-01-13 | 2010-07-29 | Konica Minolta Business Technologies Inc | インクジェット記録用シアンインク |
| US8440641B2 (en) * | 2009-03-20 | 2013-05-14 | Case Western Reserve University | Phthalocyanine salt formulations |
| US10766915B2 (en) | 2013-03-15 | 2020-09-08 | Sherri Ann McFARLAND | Metal-based coordination complexes as photodynamic compounds and their use |
| JP6767695B2 (ja) | 2018-03-29 | 2020-10-14 | パナソニックＩｐマネジメント株式会社 | 組成物、近赤外光電変換素子および撮像装置 |
| WO2019188118A1 (ja) * | 2018-03-29 | 2019-10-03 | パナソニックＩｐマネジメント株式会社 | 組成物、光電変換素子および撮像装置 |
| WO2024225218A1 (ja) * | 2023-04-25 | 2024-10-31 | キヤノン株式会社 | 一重項酸素の発生方法、一重項酸素の発生システム、一重項酸素の発生キット、及び一重項酸素発生剤 |
| CN117659113A (zh) * | 2023-12-04 | 2024-03-08 | 福建师范大学 | 胆固醇和三苯基膦基修饰不对称轴向取代硅(ⅳ)酞菁及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0344891A2 (en) * | 1988-04-07 | 1989-12-06 | Hitachi Chemical Co., Ltd. | Tetraazaporphin, process for producing the same, as well as optical recording media using the same and production processes thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3094536A (en) * | 1961-01-03 | 1963-06-18 | Malcolm E Kenney | Silicon phthalocyanines |
| US3094535A (en) * | 1961-01-03 | 1963-06-18 | Malcolm E Kenney | Germanium phthalocyanines |
| US5109016A (en) * | 1988-05-23 | 1992-04-28 | Georgia State University Foundation, Inc. | Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions |
| DE3829851A1 (de) * | 1988-09-02 | 1990-03-08 | Basf Ag | Tetraazaporphyrine sowie strahlungsempfindliche beschichtungsfilme |
| US5457195A (en) * | 1989-12-21 | 1995-10-10 | Board Of Regents, The University Of Texas System | Sapphyrin derivatives and conjugates |
| ATE108328T1 (de) * | 1990-04-03 | 1994-07-15 | Ciba Geigy Ag | Parenteral applizierbare liposomenformulierung aus synthetischen lipiden. |
| ATE206395T1 (de) * | 1990-05-15 | 2001-10-15 | Hyperion Inc | Fluoreszierende porphyrin- und fluoreszierende phthalocyanin-polyethylenglykol-, polyol- und saccharidderivate als fluoreszierende sonden |
| US5120649A (en) * | 1990-05-15 | 1992-06-09 | New York Blood Center, Inc. | Photodynamic inactivation of viruses in blood cell-containing compositions |
| CA2082934C (en) * | 1990-05-15 | 2003-08-05 | Walter B. Dandliker | Phthalocyanatopolyethylene glycol, and phthalocyanato saccharides as fluorescent digoxin reagents |
| US5166197A (en) * | 1990-07-17 | 1992-11-24 | Kenney Malcolm E | Phthalocyanine photosensitizers for photodynamic therapy |
| EP0491951B1 (en) * | 1990-07-23 | 1998-08-26 | Hitachi Chemical Co., Ltd. | Perfluoroalkylated naphthalocyanine derivative, production thereof, and optical recording medium |
| GB9123814D0 (en) * | 1991-11-08 | 1992-01-02 | Johnson Matthey Plc | Photosensitizers |
| TW235298B (enExample) * | 1992-02-27 | 1994-12-01 | Ciba Geigy |
-
1993
- 1993-02-04 TW TW082100745A patent/TW235298B/zh active
- 1993-02-18 SG SG1996001068A patent/SG49615A1/en unknown
- 1993-02-18 EP EP93810100A patent/EP0558449B1/de not_active Expired - Lifetime
- 1993-02-18 DE DE59310096T patent/DE59310096D1/de not_active Expired - Fee Related
- 1993-02-18 ES ES93810100T patent/ES2151502T3/es not_active Expired - Lifetime
- 1993-02-18 AT AT93810100T patent/ATE196143T1/de not_active IP Right Cessation
- 1993-02-18 PT PT93810100T patent/PT558449E/pt unknown
- 1993-02-18 DK DK93810100T patent/DK0558449T3/da active
- 1993-02-24 FI FI930831A patent/FI930831A7/fi unknown
- 1993-02-24 AU AU33768/93A patent/AU662800B2/en not_active Ceased
- 1993-02-25 NZ NZ247000A patent/NZ247000A/en unknown
- 1993-02-25 US US08/022,246 patent/US5358940A/en not_active Expired - Fee Related
- 1993-02-25 CA CA002090772A patent/CA2090772A1/en not_active Abandoned
- 1993-02-26 KR KR1019930002814A patent/KR100270284B1/ko not_active Expired - Fee Related
- 1993-02-26 ZA ZA931382A patent/ZA931382B/xx unknown
- 1993-02-26 HU HU9300554A patent/HUT64075A/hu unknown
- 1993-02-26 IL IL104874A patent/IL104874A/en not_active IP Right Cessation
- 1993-02-26 MX MX9301083A patent/MX9301083A/es not_active IP Right Cessation
- 1993-02-26 NO NO93930719A patent/NO930719L/no unknown
- 1993-02-26 CN CN93102147A patent/CN1044476C/zh not_active Expired - Fee Related
- 1993-02-26 JP JP5038723A patent/JPH0656839A/ja active Pending
-
1994
- 1994-06-30 US US08/269,290 patent/US5670491A/en not_active Expired - Fee Related
-
1995
- 1995-12-15 US US08/573,102 patent/US5686439A/en not_active Expired - Fee Related
-
2000
- 2000-11-22 GR GR20000402576T patent/GR3034887T3/el not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0344891A2 (en) * | 1988-04-07 | 1989-12-06 | Hitachi Chemical Co., Ltd. | Tetraazaporphin, process for producing the same, as well as optical recording media using the same and production processes thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| NO930719L (no) | 1993-08-30 |
| CN1075966A (zh) | 1993-09-08 |
| NZ247000A (en) | 1995-07-26 |
| DE59310096D1 (de) | 2000-10-12 |
| CA2090772A1 (en) | 1993-08-28 |
| MX9301083A (es) | 1993-09-01 |
| DK0558449T3 (da) | 2001-01-02 |
| IL104874A0 (en) | 1993-06-10 |
| ZA931382B (en) | 1993-08-31 |
| US5670491A (en) | 1997-09-23 |
| ES2151502T3 (es) | 2001-01-01 |
| PT558449E (pt) | 2001-02-28 |
| HU9300554D0 (en) | 1993-05-28 |
| US5686439A (en) | 1997-11-11 |
| FI930831A7 (fi) | 1993-08-28 |
| ATE196143T1 (de) | 2000-09-15 |
| NO930719D0 (no) | 1993-02-26 |
| AU3376893A (en) | 1993-09-02 |
| HUT64075A (en) | 1993-11-29 |
| AU662800B2 (en) | 1995-09-14 |
| IL104874A (en) | 1998-06-15 |
| KR100270284B1 (ko) | 2000-10-16 |
| FI930831A0 (fi) | 1993-02-24 |
| KR930017912A (ko) | 1993-09-20 |
| GR3034887T3 (en) | 2001-02-28 |
| JPH0656839A (ja) | 1994-03-01 |
| US5358940A (en) | 1994-10-25 |
| TW235298B (enExample) | 1994-12-01 |
| EP0558449A1 (de) | 1993-09-01 |
| SG49615A1 (en) | 2001-01-16 |
| EP0558449B1 (de) | 2000-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1075966A (zh) | 螯合物和其制备方法 | |
| CN1098101A (zh) | 虾青素的制备、制备它的新中间体以及其制备 | |
| CN1053103C (zh) | 24－同－维生素－d－衍生物在制药中的应用 | |
| JPH0651689B2 (ja) | タキソ−ル誘導体類、それらの製造およびそれらを含有する製薬学的組成物 | |
| FR2679230A1 (fr) | Nouveaux derives d'analogues du taxol, leur preparation et les compositions qui les contiennent. | |
| SK53397A3 (en) | Process for the production of tocopherol and tocopherol/tocotrienol concentrates | |
| WO1993016060A1 (fr) | Nouveaux derives de la baccatine iii et de la desacetyl-10 baccatine iii, leur preparation et les compositions pharmaceutiques qui les contiennent | |
| CN1821242A (zh) | 制备二羟基酸HMG－CoA还原酶抑制剂的新方法 | |
| CN101058598A (zh) | 2α,3α－环氧－16α－溴－5α－雄甾－17－酮的合成方法 | |
| CN1019010B (zh) | 取代的β-二酮的制备方法 | |
| CN1907989A (zh) | 毛兰素盐及其制备方法和包含其的药物组合物 | |
| EP1673359B1 (en) | Process for the preparation of crystalline forms of orlistat | |
| CN1733766A (zh) | 具有镇咳祛痰活性的岩白菜素类化合物及其药物组合物 | |
| FR2669631A1 (fr) | Nouveaux derives de l'oxazolidine, leur preparation et leur emploi. | |
| CN1594341A (zh) | 人参皂苷次级苷compound K的脂肪酸酯类化合物及制备方法 | |
| CN1239492C (zh) | 具有1，6－亚甲基－[10]－轮烯并呋喃和甾体基本结构的药物及其用途 | |
| CN106957307B (zh) | 一种丹曲林钠衍生物及其制备方法 | |
| CN1727319A (zh) | 取代三环二萜邻二酚类衍生物及其制备方法和用途 | |
| CN116217394B (zh) | 一种制备丙戊酸中间体二丙基丙二酸二乙酯的方法 | |
| CN1282730A (zh) | 一类具有抗癌活性的特定结构的化合物及其生产方法 | |
| EP0360821A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ADRENOLEUCODYSTROPHY. | |
| CN1247604C (zh) | 一类氢醌和苯醌吡喃碳糖苷及其合成方法 | |
| CN1201734C (zh) | 一种硫脲衍生物在制备治疗眼黄斑变性药物中的应用 | |
| CN1646492A (zh) | 链状低聚乳酸硫酯 | |
| CN1844138A (zh) | 一种合成虎眼万年青皂甙的脱除保护基的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |